Cargando…
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
BACKGROUND: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing...
Autores principales: | Chrisanthar, Ranjan, Knappskog, Stian, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Berge, Elisabet O., Risberg, Terje, Mjaaland, Ingvil, Mæhle, Lovise, Engebretsen, Lars Fredrik, Lillehaug, Johan Richard, Lønning, Per Eystein |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518116/ https://www.ncbi.nlm.nih.gov/pubmed/18725978 http://dx.doi.org/10.1371/journal.pone.0003062 |
Ejemplares similares
-
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012) -
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011) -
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
por: Mathiesen, Randi R, et al.
Publicado: (2012) -
Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007) -
Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
por: Knappskog, Stian, et al.
Publicado: (2015)